Commercial development opportunities for Pharma, Biotech and Investors
Dr. Gil Van Bokkelen is the Chairman and CEO of Athersys, Inc. (NASDAQ: ATHX), a biopharmaceutical company based in Cleveland, Ohio that was established in 1995. He has served as Chairman of the Board of Directors at Athersys since August, 2000, and as CEO since the com…more ›
Gary Rabin's 24-year career in finance and operations has primarily encompassed investing in, managing and raising capital for small-cap and emerging growth companies. From 2007 to 2010, he was Managing Partner at GR Advisors, LLC, a hedge fund focused on media and…more ›
Michael Hunt was appointed Chief Executive Officer of ReNeuron in July 2005. Prior to ReNeuron, he spent six years at Biocompatibles International plc (sold to BTG plc) where he held a number of senior financial and general management positions. His early industrial car…more ›
Donna Skerrett - MD, MS - Chief Medical Officer As Mesoblast’s Chief Medical Officer, Dr Skerrett oversees clinical development of the antibody-based stem cell selection technology and in vitro culture processes, as well as the human clinical trial programs, while liais…more ›
Geoff MacKay has served in his current leadership role since Dec. 2003. Mr. MacKay provides Organogenesis Inc. with significant global, commercial experience spanning the pharmaceutical and biotechnology sectors. Mr MacKay has held numerous leadership positions withi…more ›
The region's largest stem cells and regenerative medicine industry conference
The stem cell and regenerative medicine industry is burgeoning to a critical mass and pioneering to
transform the future of healthcare.
Engage in a global forum with senior level decision makers at Europe’s largest executive level stem cell conference and make sure you learn from the recent successes and failures experienced during cell therapy development.
Sponsors
Come to World Stem Cells & Regenerative Medicine Congress and learn how to:
- Overcome regulatory hurdles
- Identify successful stem cell therapy
- Obtain reimbursement
- Understand Stem Cells in a new age of Drug Discovery
- Explore commercial potential in academic research
- Use stem cell technology for drug target discovery and toxicity testing
- Secure investment for stem cell product development
New co-location to 2012:
In 2012, World Stem Cells and Regenerative Medicine Congress will be co-located with the World Gene Therapy Congress for the first time. With the obvious synergies between Cell and Gene Therapy, this new brand addition will look to expand upon the number of pharma, biotech and academic organisations and representatives attending from these two burgeoning industries.
This new addition can only help to create additional value to existing and new clients of the World Stem Cells and Regenerative Medicine brand.
Who should sponsor:
- Pharmaceutical Manufacturers
- Contract research organisation
- Contract manufacturing organisation
- Equipment providers
- Biotechnology companies
- Pharmaceutical manufacturers
- Consultants
- Law firms
- Venture capitalists
- Stem cell Delivery
- Stem Cell Technology Platforms
- Law Firms
- Consultants
- Distribution and Logistics
- Cold Chain Storage
- Packaging
- Regional Development Agencies
- Biotechs
- Venture Capitalists
